

Table 5. Base case analysis

	Venetoclax with azacitidine	FLAG-Ida
Drug acquisition	¶¶	¶¶
Administration	£8,500	£11,037
Adverse events	£967	£1,146
HSCT	¶¶	¶¶
Total	¶¶	¶¶
Incremental cost	¶¶	
Overall survival (months)	8.9	10.2
Incremental overall survival (months)	-1.3	
Response rate	52%	71%*
Incremental overall response rate	-19%	

HSCT: haematopoietic stem cell transplant

*This response rate includes patients receiving FLAG-Ida and FLAG=only.

¶¶ commercial in confidence data removed